Harmony Biosciences (HRMY) Revenue & Revenue Breakdown
Harmony Biosciences Revenue Highlights
Latest Revenue (Y)
$582.02M
Latest Revenue (Q)
$172.81M
Harmony Biosciences Revenue by Period
Harmony Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $582.02M | 32.93% |
| 2022-12-31 | $437.86M | 43.35% |
| 2021-12-31 | $305.44M | 91.21% |
| 2020-12-31 | $159.74M | 2564.59% |
| 2019-12-31 | $6.00M | 100.00% |
| 2018-12-31 | - | - |
Harmony Biosciences generated $582.02M in revenue during NA 2023, up 32.93% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Harmony Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $172.81M | 11.77% |
| 2024-03-31 | $154.62M | -8.19% |
| 2023-12-31 | $168.41M | 5.08% |
| 2023-09-30 | $160.27M | 19.41% |
| 2023-06-30 | $134.22M | 12.67% |
| 2023-03-31 | $119.13M | -7.16% |
| 2022-12-31 | $128.31M | 9.47% |
| 2022-09-30 | $117.21M | 9.51% |
| 2022-06-30 | $107.03M | 25.45% |
| 2022-03-31 | $85.31M | -6.47% |
| 2021-12-31 | $91.21M | 12.98% |
| 2021-09-30 | $80.73M | 9.36% |
| 2021-06-30 | $73.82M | 23.71% |
| 2021-03-31 | $59.67M | 6.02% |
| 2020-12-31 | $56.29M | 23.41% |
| 2020-09-30 | $45.61M | 20.01% |
| 2020-06-30 | $38.01M | 91.56% |
| 2020-03-31 | $19.84M | 230.94% |
| 2019-12-31 | $6.00M | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Harmony Biosciences generated $172.81M in revenue during Q2 2024, up 11.77% compared to the previous quarter, and up 145.07% compared to the same period a year ago.
Harmony Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HRMY | Harmony Biosciences | $582.02M | $172.81M |
| TVTX | Travere Therapeutics | $145.24M | $54.12M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| FENC | Fennec Pharmaceuticals | $21.64M | $25.26M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| JANX | Janux Therapeutics | $8.08M | $1.25M |
| KRON | Kronos Bio | $6.29M | $2.69M |
| PLRX | Pliant Therapeutics | $1.58M | - |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| VRDN | Viridian Therapeutics | $314.00K | $72.00K |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| GPCR | Structure Therapeutics | - | - |
| NUVL | Nuvalent | - | - |
| GOSS | Gossamer Bio | - | $95.84M |
| INZY | Inozyme Pharma | - | - |
| VRNA | Verona Pharma | - | - |
| CERE | Cerevel Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| VTYX | Ventyx Biosciences | - | - |
| NVCT | Nuvectis Pharma | - | - |
| EWTX | Edgewise Therapeutics | - | - |
HRMY Revenue FAQ
What is Harmony Biosciences’s yearly revenue?
Harmony Biosciences's yearly revenue for 2023 was $582.02M, representing an increase of 32.93% compared to 2022. The company's yearly revenue for 2022 was $437.86M, representing an increase of 43.35% compared to 2021. HRMY's yearly revenue for 2021 was $305.44M, representing an increase of 91.21% compared to 2020.
What is Harmony Biosciences’s quarterly revenue?
Harmony Biosciences's quarterly revenue for Q2 2024 was $172.81M, a 11.77% increase from the previous quarter (Q1 2024), and a 28.76% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $154.62M, a -8.19% decrease from the previous quarter (Q4 2023), and a 29.79% increase year-over-year (Q1 2023). HRMY's quarterly revenue for Q4 2023 was $168.41M, a 5.08% increase from the previous quarter (Q3 2023), and a 31.26% increase year-over-year (Q4 2022).
What is Harmony Biosciences’s revenue growth rate?
Harmony Biosciences's revenue growth rate for the last 3 years (2021-2023) was 90.55%, and for the last 5 years (2019-2023) was 9608.46%.